Furthermore, an anti-IL-2R IT was approved in 1999 by the U.S. Food and Drug Administration for the treatment of cutaneous T-cell lymphoma in adults [54]. This evidence concerns the gene IL2RA and primary cutaneous T-cell non-Hodgkin lymphoma.